STAT+: Feds probe Novartis over Entresto marketing and compensation to doctors
In what might become a new scandal for Novartis, federal investigators recently demanded information from the drug maker (NVS) about the pricing and marketing of one of its biggest-selling drugs, and the focus of the probe includes compensation paid to physicians.
Last month, the U.S. Department of Justice issued a civil investigative demand about Entresto, a heart failure drug that generated $924 million in sales in the third quarter, a 46% gain. The demand was disclosed by the company in a regulatory filing, but further details were not made available (see page 36). Novartis is “working with the government to provide the requested information,” a spokeswoman wrote us.
Continue to STAT+ to read the full story…
